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Available online 1 October 2016Photobiomodulation (PBM) describes the use of red or near-infrared light to stimulate, heal, regenerate, and pro-
tect tissue that has either been injured, is degenerating, or else is at risk of dying. One of the organ systems of the
human body that ismost necessary to life, andwhose optimum functioning ismostworried about by humankind
in general, is the brain. The brain suffers from many different disorders that can be classiﬁed into three broad
groupings: traumatic events (stroke, traumatic brain injury, and global ischemia), degenerative diseases (demen-
tia, Alzheimer's and Parkinson's), and psychiatric disorders (depression, anxiety, post traumatic stress disorder).
There is some evidence that all these seemingly diverse conditions can be beneﬁcially affected by applying light
to the head. There is even the possibility that PBM could be used for cognitive enhancement in normal healthy
people. In this transcranial PBM (tPBM) application, near-infrared (NIR) light is often applied to the forehead
because of the better penetration (no hair, longer wavelength). Some workers have used lasers, but recently
the introduction of inexpensive light emitting diode (LED) arrays has allowed the development of light emitting
helmets or “brain caps”. This reviewwill cover themechanisms of action of photobiomodulation to the brain, and
summarize some of the key pre-clinical studies and clinical trials that have been undertaken for diverse brain
disorders.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Photobiomodulation (PBM) as it is known today (the beneﬁcial
health beneﬁts of light therapy had been known for some time before),
was accidently discovered in 1967, when Endre Mester from Hungary
attempted to repeat an experiment recently published by McGuff in
Boston, USA [1]. McGuff had used a beam from the recently discovered
ruby laser [2], to destroy a cancerous tumor that had been experimen-
tally implanted into a laboratory rat. However (unbeknownst to
Mester) the ruby laser that had been built for him, was only a tiny frac-
tion of the power of the laser that had previously been used by McGuff.
However, instead of curing the experimental tumors with his low-
powered laser, Mester succeeded in stimulating hair regrowth and
wound healing in the rats, in the sites where the tumors had been im-
planted [3,4]. This discovery led to a series of papers describing what
Mester called “laser biostimulation”, and soon became known as “low
level laser therapy” (LLLT) [5–7].
LLLT was initially primarily studied for stimulation of wound
healing, and reduction of pain and inﬂammation in various orthopedic
conditions such as tendonitis, neck pain, and carpal tunnel syndrome
[8]. The advent of light emitting diodes (LED) led to LLLT being renamed
as “low level light therapy”, as it became more accepted that the use of
coherent lasers was not absolutely necessary, and a second renaming
occurred recently [9] when the term PBM was adopted due to uncer-
tainties in the exact meaning of “low level”.
2. Mechanisms of action of photobiomodulation
2.1. Mitochondria and cytochrome c oxidase
The most well studied mechanism of action of PBM centers around
cytochrome c oxidase (CCO), which is unit four of the mitochondrial
respiratory chain, responsible for the ﬁnal reduction of oxygen to
water using the electrons generated from glucose metabolism [10].
The theory is that CCO enzyme activity may be inhibited by nitric
oxide (NO) (especially in hypoxic or damaged cells). This inhibitory
NO can be dissociated by photons of light that are absorbed by CCO
(which contains two heme and two copper centers with different
absorption spectra) [11]. These absorption peaks are mainly in the red
(600–700 nm) and near-infrared (760–940 nm) spectral regions.
When NO is dissociated, the mitochondrial membrane potential is in-
creased, more oxygen is consumed, more glucose is metabolized and
more ATP is produced by the mitochondria.
2.2. Reactive oxygen species, nitric oxide, blood ﬂow
It has been shown that there is a brief increase in reactive oxygen
species (ROS) produced in themitochondriawhen they absorb the pho-
tons delivered during PBM. The idea is that this burst of ROSmay trigger
somemitochondrial signaling pathways leading to cytoprotective, anti-
oxidant and anti-apoptotic effects in the cells [12]. The NO that isreleased by photodissociation acts as a vasodilator as well as a dilator
of lymphatic ﬂow. Moreover NO is also a potent signaling molecule
and can activate a number of beneﬁcial cellular pathways [13]. Fig. 2
illustrates these mechanisms.
2.3. Light sensitive ion channels and calcium
It is quite clear that theremust be some other type of photoacceptor,
in addition to CCO, as is clearly demonstrated by the fact that wave-
lengths substantially longer than the red/NIR wavelengths discussed
above, can also produce beneﬁcial effects is some biological scenarios.
Wavelengths such as 980 nm [14,15], 1064 nm laser [16], and
1072 nm LED [17], and even broad band IR light [18] have all been re-
ported to carry out PBM type effects. Although the photoacceptor for
these wavelengths has by no means been conclusively identiﬁed, the
leading hypothesis is that it is primarily water (perhaps nanostructured
water) located in heat or light sensitive ion channels. Clear changes in
intracellular calcium can be observed, that could be explained by
light-mediated opening of calcium ion channels, such as members of
the transient receptor potential (TRP) super-family [19]. TRP describes
a large family of ion channels typiﬁed by TRPV1, recently identiﬁed as
the biological receptor for capsaicin (the active ingredient in hot chili
peppers) [20]. The biological roles of TRP channels are multifarious,
but many TRP channels are involved in heat sensing and thermoregula-
tion [21].
2.4. Signaling mediators and activation of transcription factors
Most authors suggest that the beneﬁcial effects of tPBM on the brain
can be explained by increases in cerebral blood ﬂow, greater oxygen
availability and oxygen consumption, improved ATP production and
mitochondrial activity [22–24]. However there are many reports that a
brief exposure to light (especially in the case of experimental animals
that have suffered some kind of acute injury or traumatic insult) can
have effects lasting days, weeks or even months [25]. This long-lasting
effect of light can only be explained by activation of signaling pathways
and transcription factors that cause changes in protein expression that
last for some considerable time. The effects of PBM on stimulating
mitochondrial activity and blood ﬂow is of itself, unlikely to explain
long-lasting effects. A recent review listed no less than fourteen
different transcription factors and signaling mediators, that have been
reported to be activated after light exposure [10].
Fig. 1 illustrates two of the most important molecular photorecep-
tors or chromophores (cytochrome c oxidase and heat-gated ion chan-
nels) inside neuronal cells that absorb photons that penetrate into the
brain. The signaling pathways and activation of transcription factors
lead to the eventual effects of PBM in the brain.
Fig. 2 illustrates some more tissue speciﬁc mechanisms that lead on
from the initial photon absorption effects explained in Fig. 1. A wide va-
riety of processes can occur that can beneﬁt a correspondingly wide
range of brain disorders. These processes can be divided into short-
Fig. 1.Molecular and intracellular mechanisms of transcranial low level laser (light) or photobiomodulation. AP1, activator protein 1; ATP, adenosine triphosphate; Ca2+, calcium ions;
cAMP, cyclic adenosine monophosphate; NF-kB, nuclear factor kappa B; NO, nitric oxide; ROS, reactive oxygen species; TRPV, transient receptor potential vanilloid.
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tion, less edema). Another group of processes center around neuropro-
tection (upregulation of anti-apoptotic proteins, less excitotoxity, more
antioxidants, less inﬂammation). Finally a group of processes that can
be grouped under “help the brain to repair itself” (neurotrophins,
neurogenesis and synaptogenesis).
2.5. Biphasic dose response and effect of coherence
The biphasic dose response (otherwise known as hormesis, and
reviewed extensively by Calabrese et al. [26]) is a fundamentalFig. 2. Tissue speciﬁc processes that occur after PBM and beneﬁt a range of brain disorders. BD
factor; NT-3, neurotrophin 3; PBM, photobiomodulation; SOD, superoxide dismutase.biological law describing how different biological systems can be
activated or stimulated by low doses of any physical insult or chemical
substance, no matter how toxic or damaging this insult may be in
large doses. The most well studied example of hormesis is that of ioniz-
ing radiation, where protective mechanisms are induced by very low
exposures, that can not only protect against subsequent large doses of
ionizing radiation, but can even have beneﬁcial effects against diseases
such as cancer using whole body irradiation [27].
There are many reports of PBM following a biphasic dose response
(sometimes called obeying the Arndt-Schulz curve [28,29]. A low dose
of light is beneﬁcial, but raising the dose produces progressively lessNF, brain-derived neurotrophic factor; LLLT, low level light therapy; NGF, nerve growth
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light [30]. It is often said in this context that “more does not mean
more”.
Another question that arises in the ﬁeld of PBM is whether the co-
herent monochromatic lasers that were used in the original discovery
of the effect, and whose use continued for many years, are superior to
the rather recent introduction of LEDs, that are non-coherent and have
a wider band-spread (generally 30 nm full-width half-maximum).
Although there are one or two authors who continue to believe that
coherent lasers are superior [31],most commentators feel that other pa-
rameters such as wavelength, power density, energy density and total
energy are the most important determinants of efﬁcacy [8].
3. Tissue optics, direct versus systemic effects, light sources
3.1. Light penetration into the brain
Due to the growing interest in PBMof the brain, several tissue optics
laboratories have investigated thepenetration of light of differentwave-
lengths through the scalp and the skull, and to what depths into the
brain this light can penetrate. This is an intriguing question to consider,
because at present it is unclear exactly what threshold of power density
in mW/cm2 is required in the b5rain to have a biological effect. There
clearly must be a minimum value below which the light can be deliv-
ered for an inﬁnite time without doing anything, but whether this is
in the region of μW/cm2 or mW/cm2 is unknown at present.
Functional near-infrared spectroscopy (fNIRS) using 700–900 nm
light has been established as a brain imaging technique that can be
compared to functional magnetic resonance imaging (fMRI) [32].
Haeussinger et al. estimated that the mean penetration depth (5%
remaining intensity) of NIR light through the scalp and skull was
23:6 + 0:7 mm [33]. Other studies have found comparable results
with variations depending on the precise location on the head and
wavelength [34,35].
Jagdeo et al. [36] used human cadaver heads (skull with intact soft
tissue) tomeasure penetration of 830 nm light, and found that penetra-
tion depended on the anatomical region of the skull (0.9% at the tempo-
ral region, 2.1% at the frontal region, and 11.7% at the occipital region).
Red light (633 nm) hardly penetrated at all. Tedord et al. [37] also
used human cadaver heads to compare penetration of 660 nm,
808 nm, and 940 nm light. They found that 808 nm light was best and
could reach a depth in the brain of 40–50 mm. Lapchak et al. compared
the transmission of 810 nm light through the skulls of four different
species, and found mouse transmitted 40%, while for rat it was 21%,
rabbit it was 11.3 and for human skulls it was only 4.2% [38]. Pitzschke
and colleagues compared penetration of 670 nm and 810 nm light
into the brain when delivered by a transcranial or a transphenoidal ap-
proach, and found that the best combination was 810 nm delivered
transphenoidally [39]. In a subsequent study these authors compared
the effects of storage and processing (frozen or formalin-ﬁxed) on the
tissue optical properties of rabbit heads [40]. Yaroslavsky et al. exam-
ined light penetration of different wavelengths through different parts
of the brain tissue (white brain matter, gray brain matter, cerebellum,
and brainstem tissues, pons, thalamus). Best penetration was found
with wavelengths between 1000 and 1100 nm [41].
Henderson and Morries found that between 0.45% and 2.90% of
810 nm or 980 nm light penetrated through 3 cm of scalp, skull and
brain tissue in ex vivo lamb heads [42].
3.2. Systemic effects
It is in fact very likely that the beneﬁcial effects of PBM on the brain
cannot be entirely explained by penetration of photons through the
scalp and skull into the brain itself. There have been some studies that
have explicitly addressed this exact issue. In a study of PBM for
Parkinson's disease in a mouse model [43]. Mitrofanis and colleaguescompared delivering light to the mouse head, and also covered up the
head with aluminum foil so that they delivered light to the remainder
of the mouse body. They found that there was a highly beneﬁcial effect
on neurocognitive behavior with irradiation to the head, but neverthe-
less there was also a statistically signiﬁcant (although less pronounced
beneﬁt, referred to by these authors as an ‘abscopal effect”) when the
head was shielded from light [44]. Moreover Oron and co-workers
[45] have shown that delivering NIR light to the mouse tibia (using ei-
ther surface illumination or a ﬁber optic) resulted in improvement in
a transgenic mouse model of Alzheimer's disease (AD). Light was deliv-
eredweekly for 2months, starting at 4months of age (progressive stage
of AD). They showed improved cognitive capacity and spatial learning,
as compared to sham-treated AD mice. They proposed that the mecha-
nism of this effect was to stimulate c-kit-positive mesenchymal stem
cells (MSCs) in autologous bone marrow (BM) to enhance the capacity
of MSCs to inﬁltrate the brain, and clear β-amyloid plaques [46]. It
should be noted that the calvarial bone marrow of the skull contains
substantial numbers of stem cells [47].
3.3. Laser acupuncture
Laser acupuncture is often used as an alternative or as an addition to
traditional Chinese acupuncture using needles [48]. Many of the appli-
cations of laser acupuncture have been for conditions that affect the
brain [49] such as Alzheimer's disease [50] and autism [51] that have
all been investigated in animal models. Moreover laser acupuncture
has been tested clinically [52].
3.4. Light sources
A wide array of different light sources (lasers and LEDs) have been
employed for tPBM. One of the most controversial questions which re-
mains to be conclusively settled, is whether a coherent monochromatic
laser is superior to non-coherent LEDs typically having a 30 nm band-
pass (full width half maximum). Although wavelengths in the NIR
region (800–1100 nm) have been themost often used, redwavelengths
have sometimes been used either alone, or in combination with
NIR. Power levels have also varied markedly from Class IV lasers with
total power outputs in the region of 10W [53], to laserswithmoremod-
est power levels (circa 1 W). LEDs can also have widely varying total
power levels depending on the size of the array and the number and
power of the individual diodes. Power densities can also vary quite sub-
stantially from the Photothera laser [54] and other class IV lasers , which
required active cooling (~700 mW/cm2) to LEDs in the region of 10–30
mW/cm2.
3.5. Usefulness of animal models when testing tPBM for brain disorders
One question that is always asked in biomedical research, is how
closely do the laboratory models of disease (which are usually mice or
rats) mimic the human disease for which new treatments are being
sought? This is no less critical a question when the areas being studied
include brain disorders and neurology. There now exist a plethora of
transgenic mouse models of neurological disease [55,56]. However in
the present case, where the proposed treatment is almost completely
free of any safety concerns, or any reported adverse side effects, it can
be validly questioned as to why the use of laboratory animal models
should be encouraged. Animalmodels undoubtedly have disadvantages
such as failure to replicate all the biological pathways found in human
disease, difﬁculty in accurately measuring varied forms of cognitive
performance, small size of mice and rats compared to humans, short
lifespan affecting the development of age related diseases, and lack of
lifestyle factors that adversely affect human diseases. Nevertheless,
small animal models are less expensive, and require much less time
and effort to obtain results than human clinical trials, so it is likely
they will continue to be used to test tPBM for the foreseeable future.
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4.1. Animal models
Perhaps the most well-investigated application of PBM to the brain,
lies in its possible use as a treatment for acute stroke [57]. Animal
models such as rats and rabbits, were ﬁrst used as laboratory models,
and these animals had experimental strokes induced by a variety of
methods andwere then treatedwith light (usually 810nm laser)within
24 h of stroke onset [58]. In these studies intervention by tLLLT within
24h hadmeaningful beneﬁcial effects. For the ratmodels, strokewas in-
duced by middle cerebral artery occlusion (MCAO) via an insertion of a
ﬁlament into the carotid artery or via craniotomy [59,60]. Stroke induc-
tion in the “rabbit small clot embolic model” (RSCEM) was by injection
of a preparation of small blood clots (made from blood taken from a
second donor rabbit) into a catheter placed in the right internal carotid
artery [61]. These studies and the treatments and results are listed in
Table 1.
CW, continuous wave; LLLT, low level light therapy; MCAO, middle
cerebral artery occlusion; NOS, nitric oxide synthase; RSCEM, rabbit
small clot embolic model; TGFβ1, transforming growth factor β1.4.2. Clinical trials for acute stroke
Treatment of acute stroke was addressed in a series of three clinical
trials called “Neurothera Effectiveness and Safety Trials” (NEST-1 [65],
NEST-2 [66], and NEST-3 [67]) using an 810 nm laser applied to the
shaved head within 24 h of patients suffering an ischemic stroke. The
ﬁrst study, NEST-1, enrolled 120 patients between the ages of 40 to
85 years of agewith a diagnosis of ischemic stroke involving a neurolog-
ical deﬁcit that could bemeasured. The purpose of this ﬁrst clinical trial
was to demonstrate the safety and effectiveness of laser therapy for
stroke within 24 h [65]. tPBM signiﬁcantly improved outcome in
human stroke patients, when applied at ~18 h post-stroke, over the en-
tire surface of the head (20 points in the 10/20 EEG system) regardless
of stroke [65]. Only one laser treatment was administered, and 5 days
later, there was signiﬁcantly greater improvement in the Real- but not
in the Sham-treated group (p b 0.05, NIH Stroke Severity Scale). This sig-
niﬁcantly greater improvement was still present at 90 days post-stroke,
where 70% of the patients treated with Real-LLLT had a successful out-
come, while only 51% of Sham-controls did. The second clinical trial,
NEST-2, enrolled 660 patients, aged 40 to 90, who were randomly
assigned to one of two groups (331 to LLLT, 327 to sham) [68]. Beneﬁcial
results (p b 0.04) were found for the moderate and moderate-severe
(but not for the severe) stroke patients, who received the Real laser pro-
tocol [68]. These results suggested that the overall severity of the indi-
vidual stroke should be taken into consideration in future studies, and
very severe patients are unlikely to recover with any kind of treatment.
The last clinical trial, NEST-3, was planned for 1000 patients enrolled.
Patients in this study were not to receive tissue plasminogen activator,
but the study was prematurely terminated by the DSMB for futilityTable 1
Reports of transcranial LLLT used for stroke in animal models.
Subject Stroke model Parameters
Rat MCAO 660 nm; 8.8 mW; 2.64 J/cm2; pulse frequency of 10 kHz
laser applied at cerebrum at 1, 5 and 10 min
Rat MCAO 808 nm; 7.5 mW/cm2; 0.9 J/cm2; 3.6 J/cm2 at cortical sur
CW and pulse wave at 70 Hz, 4 mm diameter
Rabbit RSCEM 808 nm ± 5 nm; 7.5 W/cm2, 2 min duration 3 h after st
and 25 mW/cm2 10 min duration 1 or 6 h after stroke
Rat MCAO 808 nm; 0.5 mW/cm2; 0.9 J/cm2 on brain 3 mm dorsal to
the eye and 2 mm anterior to the ear
Rabbit RSCEM 808 nm; 7.5 mW/cm2; 0.9 J/cm2; 3.6 J/cm2 at cortical sur
CW; 300 min; pulse at 1 kHz, 2 min at 100 Hz(an expected lack of statistical signiﬁcance) [67]. NEST-1 was consid-
ered successful, even though as a phase 1 trial, it was not designed to
show efﬁcacy. NEST-2 was partially successful when the patients were
stratiﬁed, to exclude very severe strokes or strokes deep within the
brain [66]. There has been considerable discussion in the scientiﬁc liter-
ature on preciselywhy the NEST-3 trial failed [69]. Many commentators
have wondered how could tPBMwork so well in the ﬁrst trial, in a sub-
group in the second trial, and fail in the third trial. Lapchak's opinion is
that themuch thicker skull of humans compared to that of the other an-
imals discussed above (mouse, rat and rabbit), meant that therapeuti-
cally effective amounts of light were unlikely to reach the brain [69].
Moreover the time between the occurrence of a stroke and initiation
of the PBMTmay be an important factor. There are reports in the litera-
ture that neuroprotection must be administered as soon as possible
after a stroke [70,71]. Furthermore, stroke trials in particular should ad-
here to the RIGOR (rigorous research) guidelines and STAIR (stroke
therapy academic industry roundtable) criteria [72]. Other contributory
causes to the failure of NEST-3 may have been included the decision to
use only one single tPBM treatment, instead of a series of treatments.
Moreover, the optimum brain areas to be treated in acute stroke remain
to be determined. It is possible that certain areas of the brain that have
sustained ischemic damage should bepreferentially illuminated andnot
others.
4.3. Chronic stroke
Somewhat surprisingly, there have not as yet been many trials of
PBM for rehabilitation of stroke patients with only the occasional report
to date. Naeser reported in an abstract the use of tPBM to treat chronic
aphasia in post-stroke patients [73]. Boonswang et al. [74] reported a
single patient case in which PBMwas used in conjunction with physical
therapy to rehabilitate chronic stroke damage. However the ﬁndings
that PBM can stimulate synaptogenesis in mice with TBI, does suggest
that tPBM may have particular beneﬁts in rehabilitation of stroke pa-
tients. Norman Doidge, in Toronto, Canada has described the use of
PBM as a component of a neuroplasticity approach to rehabilitate
chronic stroke patients [75].
5. PBM for traumatic brain injury (TBI)
5.1. Mouse and rat models
There have been a number of studies looking at the effects of PBM in
animal models of TBI. Oron's group was the ﬁrst [76] to demonstrate
that a single exposure of the mouse head to a NIR laser (808 nm) a
few hours after creation of a TBI lesion could improve neurological per-
formance and reduce the size of the brain lesion. A weight-drop device
was used to induce a closed-head injury in the mice. An 808 nm diode
laser with two energy densities (1.2–2.4 J/cm2 over 2 min of irradiation
with 10 and 20 mW/cm2) was delivered to the head 4 h after TBI was
induced. Neurobehavioral function was assessed by the neurologicalEffect References
; Suppression of NOS activity and up regulation of TGF-β1 [59]
face; Administration of LLLT 24 h after stroke onset induced
functional beneﬁt and neurogenesis induction
[60]
roke Improved behavioral performance and durable effect
after LLLT within 6 h from stroke onset
[62]
LLLT applied at different locations on the skull
improved neurological function after acute stroke
[63]
face; LLLT administered 6 h after embolic stroke resulted in
clinical improvements in rabbits
[64]
118 M.R. Hamblin / BBA Clinical 6 (2016) 113–124severity score (NSS). There were no signiﬁcant difference in NSS be-
tween the power densities (10 vs 20mW/cm2) or signiﬁcant differenti-
ation between the control and laser treated group at early time points
(24 and 48 h) post TBI. However, there was a signiﬁcant improvement
(27% lower NSS score) in the PBM group at times of 5 days to 4 weeks.
The laser treated group also showed a smaller loss of cortical tissue
than the sham group [76].
Hamblin's laboratory then went on (in a series of papers [76]) to
show that 810 nm laser (and 660 nm laser) could beneﬁt experimental
TBI both in a closed headweight dropmodel [77], and also in controlled
cortical impactmodel inmice [25].Wu et al. [77] explored the effect that
varying the laser wavelengths of LLLT had on closed-head TBI in mice.
Mice were randomly assigned to LLLT treated group or to sham group
as a control. Closed-head injury (CHI)was induced via aweight drop ap-
paratus. To analyze the severity of the TBI, the neurological severity
score (NSS) was measured and recorded. The injured mice were then
treated with varying wavelengths of laser (665, 730, 810 or 980 nm)
at an energy level of 36 J/cm2 at 4 h directed onto the scalp. The
665 nm and 810 nm groups showed signiﬁcant improvement in NSS
when compared to the control group at day 5 to day 28. Results are
shown in Fig. 3. Conversely, the 730 and 980 nm groups did not show
a signiﬁcant improvement in NSS and these wavelengths did not pro-
duce similar beneﬁcial effects as in the 665 nm and 810 nm LLLT groups
[77]. The tissue chromophore cytochrome c oxidase (CCO) is proposed
to be responsible for the underlying mechanism that produces the
many PBM effects that are the byproduct of LLLT. COO has absorption
bands around 665 nm and 810 nm while it has low absorption bands
at thewavelength of 730 nm [78]. It should be noted that this particular
study found that the 980 nm did not produce the same positive effects
as the 665 nm and 810 nm wavelengths did; nevertheless previous
studies did ﬁnd that the 980 nm wavelength was an active one for
LLLT. Wu et al. proposed that these dissimilar results may be due to
the variance in the energy level, irradiance, etc. between the other stud-
ies and this particular study [77].Fig. 3. tPBM for TBI in amousemodel. Mice received a closed head injury and 4 hours later a sin
over 4 min with spot size 1-cm diameter) [77]. A, 665 nm; B, 730 nm; C, 810 nm; D, 980 nm.Ando et al. [25] used the 810 nmwavelength laser parameters from
the previous study and varied the pulse modes of the laser in a mouse
model of TBI. These modes consisted of either pulsed wave at 10 Hz or
at 100 Hz (50% duty cycle) or continuous wave laser. For the mice, TBI
was induced with a controlled cortical impact device via open cranioto-
my. A single treatment with an 810 nm Ga-Al-As diode laser with a
power density of 50 mW/m2 and an energy density of 36 J/cm2 was
given via tLLLT to the closed head in mice for a duration of 12 min at
4 h post CCI. At 48 h to 28 days post TBI, all laser treated groups had sig-
niﬁcant decreases in the measured neurological severity score (NSS)
when compared to the control (Fig. 4A). Although all laser treated
groups had similar NSS improvement rates up to day 7, the PW 10 Hz
group began to show greater improvement beyond this point as seen
in Fig. 4. At day 28, the forced swim test for depression and anxiety
was used and showed a signiﬁcant decrease in the immobility time for
the PW 10 Hz group. In the tail suspension test which measures
depression and anxiety, there was also a signiﬁcant decrease in the
immobility time at day 28, and this time also at day 1, in the PW
10 Hz group.
Studies using immunoﬂuorescence of mouse brains showed that
tPBM increased neuroprogenitor cells in the dentate gyrus (DG) and
subventricular zone at 7 days after the treatment [79]. The neurotrophin
called brain derived neurotrophic factor (BDNF) was also increased in
the DG and SVZ at 7 days , while the marker (synapsin-1) for synapto-
genesis and neuroplasticity was increased in the cortex at 28 days but
not in the DG, SVZ or at 7 days [80] (Fig. 4B). Learning and memory as
measured by the Morris water maze was also improved by tPBM [81].
Whalen's laboratory [82] andWhelan's laboratory [83] also successfully
demonstrated therapeutic beneﬁts of tPBM for TBI in mice and rats
respectively.
Zhang et al. [84] showed that secondary brain injury occurred to a
worse degree in mice that had been genetically engineered to lack “Im-
mediate Early Response” gene X-1 (IEX-1) when exposed to a gentle
head impact (this injury is thought to closely resemble mild TBI ingle exposure of the head to one of four different lasers (36 J/cm2 delivered at 150mW/cm2
Fig. 4. tPBM for controlled cortical impact TBI in amousemodel. (A)Mice received a single exposure (810 nm laser, 36 J/cm2 delivered at 50mW/cm2 over 12min) [121]. (B)Mice received
3 daily exposures starting 4 h post-TBI andwere sacriﬁced after 7 or 28 days. BDNF and neurogenesis (BrdU)were increased at 7 days [81], while synaptogenesis was increased at 28 days
[80].
119M.R. Hamblin / BBA Clinical 6 (2016) 113–124humans). Exposing IEX-1 knockout mice to LLLT 4 h post injury,
suppressed proinﬂammatory cytokine expression of interleukin (IL)-Iβ
and IL-6, but upregulated TNF-α. The lack of IEX-1 decreased ATP pro-
duction, but exposing the injured brain to LLLT elevated ATP production
back to near normal levels.
Dong et al. [85] even further improved the beneﬁcial effects of PBM
on TBI in mice, by combining the treatment with metabolic substrates
such as pyruvate and/or lactate. The goal was to even further improve
mitochondrial function. This combinatorial treatment was able to re-
verse memory and learning deﬁcits in TBI mice back to normal levels,
as well as leaving the hippocampal region completely protected from
tissue loss; a stark contrast to that found in control TBI mice that exhib-
ited severe tissue loss from secondary brain injury.
5.2. TBI in humans
Margaret Naeser and collaborators have tested PBM in human sub-
jects who had suffered TBI in the past [86]. Many sufferers from severe
or even moderate TBI, have very long lasting and even life-changing
sequelae (headaches, cognitive impairment, and difﬁculty sleeping)
that prevent them working or living any kind or normal life. TheseFig. 5. tPBM for Alzheimer's disease. (A) Nineteen patients were randomized to receive real or
(improved cognitive performance) in real but not sham (unpublished data).individuals may have been high achievers before the accident that
caused damage to their brain [87]. Initially Naeser published a report
[88] describing two cases she treated with PBM applied to the fore-
head twice a week. A 500 mW continuous wave LED source (mixture
of 660 nm red and 830 nm NIR LEDs) with a power density of 22.2
mW/cm2 (area of 22.48 cm2), was applied to the forehead for a typ-
ical duration of 10min (13.3 J/cm2). In the ﬁrst case study the patient
reported that she could concentrate on tasks for a longer period of
time (the time able to work at a computer increased from 30 min
to 3 h). She had a better ability to remember what she read, de-
creased sensitivity when receiving haircuts in the spots where LLLT
was applied, and improved mathematical skills after undergoing LLLT.
The second patient had statistically signiﬁcant improvements com-
pared to prior neuropsychological tests after 9 months of treatment.
The patient had a 2 standard deviation (SD) increase on tests of inhibi-
tion and inhibition accuracy (9th percentile to 63rd percentile on the
Stroop test for executive function and a 1 SD increase on the Wechsler
Memory scale test for the logical memory test (83rd percentile to
99th percentile) [89].
Naeser et al. then went on to report a case series of a further eleven
patients [90]. This was an open protocol study that examined whethersham tPBM (810 nm LED, 24.6 J/cm2 at 41 mW/cm2). (B) Signiﬁcant decline in ADAS-cog
Fig. 6. tPBM for major depression and anxiety in humans. (A) Ten patients received a single exposure to the forehead (810 LED, 60 J/cm2 delivered at 250 mW/cm2). (B) Mean Hamilton
score for depression at baseline and at two weeks post-treatment [109].
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nition in patients with chronic, mild traumatic brain injury (mTBI). This
study had 11 participants ranging in age from 26 to 62 (6 males, 5
females) who suffered from persistent cognitive dysfunction after
mTBI. The participants' injurieswere caused bymotor vehicle accidents,
sports related events and for one participant, an improvised explosive
device (IED) blast. tLLLT consisted of 18 sessions (Monday, Wednesday,
and Friday for 6 weeks) and commenced anywhere from 10 months to
8 years post-TBI. A total of 11 LED clusters (5.25 cm in diameter,
500 mW, 22.2 mW/cm2, 13 J/cm2) were applied for about 10 min per
session (5 or 6 LED placements per set, Set A and then Set B, in each ses-
sion). Neuropsychological testing was performed pre-LED application
and 1 week, 1 month and 2 months after the ﬁnal treatment. Naeser
and colleagues found that there was a signiﬁcant positive linear trend
observed for the Stroop Test for executive function, in trial 2 inhibition
(p=0.004); Stroop, trial 4 inhibition switching (p= 0.003); California
Verbal Learning Test (CVLT)-II, total trials 1–5 (p=0.003); CVLT-II, long
delay free recall (p=0.006). Improved sleep and fewer post-traumatic
stress disorder (PTSD) symptoms, if present beforehand, were observed
after treatment. Participants and family members also reported better
social function and a better ability to perform interpersonal and occupa-
tional activities. Although these results were signiﬁcant, further
placebo-controlled studies will be needed to ensure the reliability of
this these data [90].
Henderson and Morries [91] used a high-power NIR laser (10–15W
at 810 and 980 nm) applied to the head to treat a patientwithmoderate
TBI. The patient received 20 NIR applications over a 2-month period.
They carried out anatomical magnetic resonance imaging (MRI) and
perfusion single-photon emission computed tomography (SPECT). The
patient showed decreased depression, anxiety, headache, and insomnia,
whereas cognition and quality of life improved, accompanied by chang-
es in the SPECT imaging.6. PBM for Alzheimer's disease (AD)
6.1. Animal models
There was a convincing study [92] carried out in an AβPP transgenic
mouse of AD. tPBM (810 nm laser) was administered at different doses
3 times/week for 6 months starting at 3 months of age. The numbers of
Aβ plaques were signiﬁcantly reduced in the brain with administration
of tPBM in a dose-dependent fashion. tPBMmitigated the behavioral ef-
fects seen with advanced amyloid deposition and reduced the expres-
sion of inﬂammatory markers in the transgenic mice. In addition, TLT
showed an increase in ATP levels, mitochondrial function, and c-fosexpression suggesting that there was an overall improvement in neuro-
logical function.
6.2. Humans
There has been a group of investigators in Northern England who
have used a helmet built with 1072 nm LEDs to treat AD, but some-
what surprisingly no peer-reviewed publications have described
this approach [93]. However a small pilot study (19 patients) that
took the form of a randomized placebo-controlled trial investigated
the effect of the Vielight Neuro system (see Fig. 5A) (a combination
of tPBM and intranasal PBM) on patients with dementia and mild
cognitive impairment [94]. This was a controlled single blind pilot
study in humans to investigate the effects of PBM on memory and
cognition. 19 participants with impaired memory/cognition were
randomized into active and sham treatments over 12 weeks with a
4-week no-treatment follow-up period. They were assessed with MMSE
and ADAS-cog scales. The protocol involved in-clinic use of a combined
transcranial-intranasal PBM device; and at-home use of an intranasal-
only PBM device and participants/ caregivers noted daily experiences in
a journal. Active participants with moderate to severe impairment
(MMSE scores 5–24) showed signiﬁcant improvements (5-points
MMSE score) after 12 weeks. There was also a signiﬁcant improvement
in ADAS-cog scores (see Fig. 5B). They also reported better sleep, fewer
angry outbursts and decreased anxiety and wandering. Declines were
noted during the 4-week no-treatment follow-up period. Participants
with mild impairment to normal (MMSE scores of 25 to 30) in both the
active and sham sub-groups showed improvements. No related adverse
events were reported.
An interesting paper from Russia [95] described the use of intravas-
cular PBM to treat 89 patients with ADwho received PBM (46 patients)
or standard treatment with memantine and rivastigmine (43 patients).
The PBM consisted of threading a ﬁber-optic through a cathéter in
the fémoral artery and advancing it to the distal site of the anterior
and middle cerebral arteries and delivering 20 mW of red laser for
20–40 min. The PBM group had improvement in cerebral microcircula-
tion leading to permanent (from 1 to 7 years) reduction in dementia
and cognitive recovery.
7. Parkinson's disease
The majority of studies on PBM for Parkinson's disease have been
in animalmodels and have come from the laboratory of JohnMitrofanis
in Australia [96]. Two basic models of Parkinson's disease were
used. The ﬁrst employed administration of the small molecule (MPTP
or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to mice [97]. MPTP
Table 2
List of brain disorders that may in principle be treated by tPBM.
Type of brain disorder
Traumatic Neurodegenerative Psychiatric Neurodevelopmental
Acute stroke Alzheimer's disease Depression (major, bipolar,
suicidal ideation)
Autism (autism spectrum disorder)
Chronic stroke Parkinson's disease Psychosis (schizophrenia) Attention deﬁcit hyperactivity
disorder (ADHD)
Acute TBI Other dementias (vascular, Lewy bodies, frontotemporal) Post traumatic stress disorder (PTSD)
Chronic TBI Chronic traumatic encephalopathy Addiction
Global ischemia Amyotrophic lateral sclerosis (Lou Gehrig's disease) Insomnia
Coma (vegetative state) Primary progressive aphasia
Birth trauma (neonatal stroke) Prion diseases (Creutzfeldt-Jakob)
“Chemo-brain” Huntington's disease
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Parkinson's like symptoms (loss of substantia nigra cells) in young peo-
ple who had taken this drug [98]. Mice were treated with tPBM (670-
nm LED, 40 mW/cm2, 3.6 J/cm2) 15 min after each MPTP injection re-
peated 4 times over 30 h. There were signiﬁcantly more (35%–45%) do-
paminergic cells in the brains of the tPBM treated mice [97]. A
subsequent study showed similar results in a chronic mouse model of
MPTP-induced Parkinson's disease [99]. They repeated their studies in
another mouse model of Parkinson's disease, the tau transgenic mouse
strain (K3) that has a progressive degeneration of dopaminergic cells
in the substantia nigra pars compacta (SNc) [100]. They went on to
test a surgically implanted intracranial ﬁber designed to deliver either
670 nm LED (0.16 mW) or 670 nm laser (67 mW) into the lateral ven-
tricle of the brain in MPTP-treatedmice [101]. Both low power LED and
high power laserwere effective in preserving SNc cells, but the laserwas
considered to be unsuitable for long-term use (6 days) due to excessive
heat production. As mentioned above, these authors also reported a
protective effect of abscopal light exposure (head shielded) in this
mouse model [43]. Recently this group has tested their implanted
ﬁber approach in amodel of Parkinson's disease in adult Macaquemon-
keys treated with MPTP [102]. Clinical evaluation of Parkinson's symp-
toms (posture, general activity, bradykinesia, and facial expression) in
the monkeys were improved at low doses of light (24 J or 35 J) com-
pared to high doses (125 J) [103].
The only clinical report of PBM for Parkinson's disease in humans
was an abstract presented in 2010 [104]. Eight patients between 18
and 80 years with late stage PD participated in a non-controlled, non-
randomized study. Participants received tPBM treatments of the head
designed to deliver light to the brain stem, bilateral occipital, parietal,
temporal and frontal lobes, and treatment along the sagittal suture. A
Visual Analog Scale (VAS), was used to record the severity of their
symptoms of balance, gait, freezing, cognitive function, rolling in bed,
and difﬁculties with speech pre-procedure and at study endpoint with
10 being most severe and 0 as no symptom. Compared with baseline,
all participants demonstrated a numerical improvement in the VAS
from baseline to study endpoint. A statistically signiﬁcant reduction in
VAS rating for gait and cognitive function was observed with average
mean change of —1.87 (p b 0.05) for gait and a mean reduction
of—2.22 (p b 0.05) for cognitive function. Further, freezing and difﬁculty
with speech ratings were signiﬁcantly lower (mean reduction of 1.28
(p b 0.05) for freezing and 2.22 (p b 0.05) for difﬁculty with speech).
8. PBM for psychiatric disorders
8.1. Animal models
A common and well-accepted animal model of depression is called
“chronic mild stress” [105]. After exposure to a series of chronic unpre-
dictable mild stressors, animals develop symptoms seen in human
depression, such as anhedonia (loss of the capacity to experience plea-
sure, a core symptom of major depressive disorder), weight loss orslower weight gain, decrease in locomotor activity, and sleep disorders
[106]. Wu et al. used Wistar rats to show that after 5 weeks of chronic
stress, application of tPBM 3 times a week for 3 weeks (810 nm laser,
100 Hz with 20% duty cycle, 120 J/cm2) gave signiﬁcant improvement
in the forced swimming test (FST) [107]. In a similar study Salehpour
et al. [108] compared the effects of two different lasers (630 m nm at
89 mW/cm2, and 810 nm at 562 mW/cm2, both pulsed at 10 Hz, 50%
duty cycle). The 810 nm laser proved better than the 630 nm laser in
the FST, in the elevated plusmaze and also reduced blood cortisol levels.
8.2. Depression and anxiety
The ﬁrst clinical study in depression and anxiety was published by
Schiffer et al. in 2009 [109]. They used a fairly small area 1 W 810 nm
LED array (see Fig. 6A) applied to the forehead in patients with major
depression and anxiety. They found improvements in the Hamilton de-
pression rating scale (HAM-D) (see Fig. 6B), and the Hamilton anxiety
rating scale (HAM-A), 2 weeks after a single treatment. They also
found increases in frontal pole regional cerebral blood ﬂow (rCBF) dur-
ing the light delivery using a commercial NIR spectroscopy device.
Cassano and co-workers [110] used tPBM with an 810 nm laser (700
mW/cm2 and a ﬂuence of 84 J/cm2 delivered per session for 6 sessions
in patients with major depression. Baseline mean HAM-D17 scores de-
creased from 19.8 ± 4.4 (SD) to 13 ± 5.35 (SD) after treatment (p =
0.004).
9. Cognitive enhancement
Fromwhat we have seen above, it need come as no surprise, to learn
that there are several reports about cognitive enhancement in normal
people or healthy animals using PBM. The ﬁrst report was in middle
aged (12 months) CD1 female mice [111]. Exposure of the mice to
1072 nm LED arrays led to improved performance in a 3D maze
compared to sham treated age-matched controls. Francisco Gonzalez-
Lima at the University of Texas Austin, has worked in this area for
some time [112]. Working in rats they showed that transcranial PBM
(9 mW/cm2 with 660 nm LED array) induced a dose-dependent in-
crease in oxygen consumption of 5% after 1 J/cm2 and 16% after 5 J/
cm2 [113]. They also found that tPBM reduced fear renewal and
prevented the reemergence of extinguished conditioned fear responses
[113]. In normal human volunteers they used transcranial PBM
(1064 nm laser, 60 J/cm2 at 250 mW/cm2) delivered to the forehead
in a placebo-controlled, randomized study, to inﬂuence cognitive tasks
related to the prefrontal cortex, including a psychomotor vigilance
task (PVT), a delayed match-to-sample (DMS) memory task, and the
positive and negative affect schedule (PANAS-X) to show improved
mood [16]. Subsequent studies in normal humans showed that tPBM
with 1064 nm laser could improve performance in the Wisconsin Card
Sorting Task (considered the gold standard test for executive function)
[114]. They also showed that tPBM to the right forehead (but not the
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tion (ABM) in humans with depression [115].
A study by Salgado et al. used transcranial LED PBM on cerebral
blood ﬂow in healthy elderly women analyzed by transcranial Doppler
ultrasound (TCD) of the right and left middle cerebral artery and basilar
artery. Twenty-ﬁve non-institutionalized elderly women (mean age
72 years old), with cognitive status N24, were assessed using TCD
before and after transcranial LED therapy. tPBM (627 nm, 70 mW/cm2,
10 J/cm2)was performed at four points of the frontal and parietal region
for 30 s each twice a week for 4 weeks. There was a signiﬁcant increase
in the systolic and diastolic velocity of the leftmiddle cerebral artery (25
and 30%, respectively) and the basilar artery (up to 17 and 25%), as well
as a decrease in the pulsatility index and resistance index values of the
three cerebral arteries analyzed [116].
10. Conclusion
Many investigators believe that PBM for brain disorders will become
one of the most important medical applications of light therapy in the
coming years and decades. Despite the efforts of “Big Pharma”, prescrip-
tion drugs for psychiatric disorders are not generally regarded very highly
(either by the medical profession or by the public), and many of these
drugs perform little better than placebos in different trials, andmoreover
can also have major side-effects [117]. Moreover it is well accepted that
with the overall aging of the general population, together with ever
lengthening life spans, that dementia, Alzheimer's, and Parkinson's dis-
eases will become a global health problem [118,119]. Even after many
years of research, no drug has yet been developed to beneﬁt these neuro-
degenerative disorders. A similar state of play exists with drugs for stroke
(with the exception of clot-busting enzymes) and TBI. New indications
for tPBM such as global ischemia (brain damage after a heart attack),
post-operative cognitive dysfunction [120], and neurodevelopmental dis-
orders such as autism spectrumdisordermaywell emerge. Table 2 shows
the wide range of brain disorders and diseases that may eventually be
treated by some kind of tPBM, whether that be an ofﬁce/clinic based pro-
cedure or a home-use baseddevice. If inexpensive LEDhelmets can be de-
veloped and successfully marketed as home use devices, then we are
potentially in a position to beneﬁt large numbers of patients (to say noth-
ing of healthy individuals). Certainly the advent of the Internet has made
itmuch easier for knowledge about this kind of home treatment to spread
(almost by word of mouth so to speak).
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